[{"id":"eb48a20f-88f5-4d35-a3ff-283774b15fd3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06065462","created_at":"2023-10-04T16:11:21.780Z","updated_at":"2025-02-25T13:13:30.456Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100","source_id_and_acronym":"NCT06065462","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jemperli (dostarlimab-gxly) • LB-100"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 11/10/2023","start_date":" 11/10/2023","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2024-08-28"},{"id":"581dc62d-194b-4266-810c-929a17a1d92e","acronym":"CoLBAt","url":"https://clinicaltrials.gov/study/NCT06012734","created_at":"2023-08-25T15:08:45.087Z","updated_at":"2024-07-02T16:35:38.129Z","phase":"Phase 1","brief_title":"LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients","source_id_and_acronym":"NCT06012734 - CoLBAt","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • LB-100"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2023-09-04"}]